- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03035760
Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers
A Phase 1 Open Label, Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242-2600
- University of Iowa - Vaccine Research and Education Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and nonpregnant females between the ages of 18 and 45 years, inclusive.
Women of childbearing potential* must agree to practice adequate contraception** for the 28-day period before Day 0 through 4 months after the last dose of study medication.
* A woman is considered of childbearing potential unless surgically sterile (tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (=1 year).
**Acceptable birth control methods include but are not limited to: abstinence from sexual intercourse with men; monogamous relationship with a vasectomized partner; double-barrier methods (condoms, diaphragms, spermicides); intrauterine devices; and licensed hormonal methods.
In good health, as judged by the investigator and determined by vital signs*
*Temperature < 38°C, heart rate <= 100 bpm and > 50 bpm, systolic blood pressure <= 140 mmHg and > 89 mmHg, diastolic blood pressure <= 90 mmHg and = 60 mm Hg, medical history and a targeted physical examination. BMI >= 18 and <= 35. Athletically trained subjects with a pulse >= 45 may be enrolled at the discretion of the principal investigator or designated licensed clinical investigator. Acceptable screening laboratories: Hemoglobin, white blood cell (WBC) count, neutrophil, and platelet counts, INR and PTT within normal ranges. AST < 44 and ALT < 44 and total bilirubin, creatinine must be equal to or below the upper limit of normal (creatinine values below the normal range are acceptable). Random blood glucose must be <140. Urine dipstick testing must be negative for glucose and negative or trace for protein. The following serology tests must be negative: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. HIV and hepatitis C viral load PCR testing may be performed for individuals suspected of having indeterminate antibody testing.
- Male participants must be willing to ensure use of condoms and spermicides for 4 months after the last dose study medication.
- Provide written informed consent before initiation of any study procedures.
- Willing to be available for all study-required procedures, and visits for the duration of the study.
- Individuals must agree to abstain from drug or alcohol use for 48 hours prior to enrollment through day 10 or 14.
- Able to provide a home phone number, and the name, address, and/or email of a person willing to assist with making contact during the follow-up phase of the study.
Exclusion Criteria:
- Pregnant women, women who are planning to become pregnant in the next 4 months, or women who are breastfeeding.
- Body temperature >=100.4°F (>=38.0°C) or acute illness within 3 days before administration of study drug (subject may be rescheduled).
Chronic or acute medical disorder*
- Disorders of the cardiac, pulmonary, liver, kidney, neurologic, gastrointestinal or other system, such that in the opinion of the investigator participation in the study creates additional risk to the subject, or to the validity of the study.
- Use of chronic systemic medications* *Intermittent use of over the counter medications such as acetaminophen, ibuprofen, cold and sinus medications are permitted for enrollment Topical medications, nasal steroids are permitted throughout the study. Use of prescription medications used less than once per week on average are permitted for enrollment. If the subject has taken a short term prescription medication within the past 30 days (e.g. an antibiotic), they should be postponed from enrollment until 30 days have elapsed since the last dose.
- Has history of sensitivity to related benzimidazole compounds (e.g., albendazole, mebendazole).
- A diagnosis of schizophrenia, bipolar disease, or history of hospitalization for a psychiatric condition or previous suicide attempt.
A history of treatment for any other psychiatric disorder in the past 3 years.*
*Past treatment for ADHD does not exclude participants from enrollment as long as the medications have been discontinued for a minimum of 3 months and symptoms are well controlled.
Received an experimental agent* within 1 month before administration of study drug or expect to receive an experimental agent during the 10 or 14-day study period.
*Vaccine, drug, biologic, device, blood product, or medication.
Any condition that would, in the opinion of the investigator, interfere with the study.*
*This includes any condition that would place them at an unacceptable risk of injury, render them unable to meet the requirements of the protocol, or that may interfere with successful completion of the study.
A history of heavy alcohol* or illicit drug use**, or history of substance abuse#.
*On average, greater than 7 alcoholic drinks per week. .
**Other than occasional marijuana use (less than once per week for the past 60 days is acceptable).
#Alcohol or illicit drugs within the past 3 years.
- History of chronic tobacco use in the past 60 days.* *A history of occasional tobacco use (less than 1 pack per week on average) is acceptable. Individuals will be counseled to abstain from use of tobacco and marijuana from screening through day 10 or 14.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
3 mg/kg orally once daily for 5 days (n = 8)
|
methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic.
It is the sulphoxide metabolite of fenbendazole.
|
EXPERIMENTAL: 2
7.5 mg/kg orally once daily for 5 days (n = 8)
|
methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic.
It is the sulphoxide metabolite of fenbendazole.
|
EXPERIMENTAL: 3
15 mg/kg orally once daily for 5 days (n = 8)
|
methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic.
It is the sulphoxide metabolite of fenbendazole.
|
EXPERIMENTAL: 4
3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
|
methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic.
It is the sulphoxide metabolite of fenbendazole.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arms 1, 2, and 3
Time Frame: Day 1 through Day 10
|
All adverse events, defined as any untoward medical occurrence regardless of its causal relationship to the study treatment, were collected for 14 days after dosing.
The PI then determined relatedness to the study drug.
Related was defined as "there is a reasonable possibility that the study product caused the adverse event.
Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event."
|
Day 1 through Day 10
|
Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arm 4
Time Frame: Day 1 through Day 14
|
All adverse events, defined as any untoward medical occurrence regardless of its causal relationship to the study treatment, were collected for 14 days after dosing.
The PI then determined relatedness to the study drug.
Related was defined as "there is a reasonable possibility that the study product caused the adverse event.
Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event."
|
Day 1 through Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Concentration Time-curve for a Single Dosing Interval (AUCtau) of Oxfendazole for Arm 1, 2 and 3
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on day 1 and 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 72, 120 hours post-dose on day 5
|
AUCtau was defined as the total area under the concentration-time curve from dosing to the end of the 24-hour dosing interval for Dose 1 and Dose 5. AUCtau was calculated using the Linear Up Log Down calculation method.
|
0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on day 1 and 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 72, 120 hours post-dose on day 5
|
Area Under the Concentration Time-curve to the Time of Last Measured Concentration (AUClast) of Oxfendazole for Arm 4
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose
|
AUClast was defined as the area under the concentration-time curve from dosing to the time of the last measured concentration of that dosing period greater than the lower limit of quantification of the bioanalytical assay.
AUClast was calculated using the Linear Up Log Down calculation method.
|
0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose
|
Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma for Arms 1, 2, and 3
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on day 1 and 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 72, 120 hours post-dose on day 5
|
Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations computed from concentrations that were measured using a validated HPLC-MS/MS method.
|
0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on day 1 and 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 72, 120 hours post-dose on day 5
|
Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma for Arm 4
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose
|
Cmax is defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations computed from concentrations that were measured using a validated HPLC-MS/MS method.
|
0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose
|
Terminal Elimination Half-life (t1/2) of Oxfendazole for Arms 1, 2, and 3
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on day 1 and 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 72, 120 hours post-dose on day 5
|
The apparent terminal elimination half-life (t1/2) was defined as the time required for the drug concentration to decrease by a factor of one-half in the terminal phase computed from concentrations that were measured using a validated HPLCMS/MS method.
|
0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on day 1 and 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 72, 120 hours post-dose on day 5
|
Terminal Elimination Half-life (t1/2) of Oxfendazole for Arm 4
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose
|
The apparent terminal elimination half-life (t1/2) was defined as the time required for the drug concentration to decrease by a factor of one-half in the terminal phase computed from concentrations that were measured using a validated HPLCMS/MS method.
|
0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose
|
Time of Maximum Observed Concentration (Tmax) of Oxfendazole for Arms 1, 2, and 3
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on day 1 and 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 72, 120 hours post-dose on day 5
|
Tmax was defined as the time at which the maximum concentration (Cmax) occurs in plasma computed from concentrations that were measured using a validated HPLCMS/MS method.
|
0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on day 1 and 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 72, 120 hours post-dose on day 5
|
Time of Maximum Observed Concentration (Tmax) of Oxfendazole for Arm 4
Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose
|
Tmax was defined as the time at which the maximum concentration (Cmax) occurs in plasma computed from concentrations that were measured using a validated HPLCMS/MS method.
|
0, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-0005
- HHSN272201300020I
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helminthic Infection
-
University GhentFlemish Interuniversity Council (VLIR); Arba Minch University, EthiopiaCompletedVitamin A Deficiency | Anemia, Iron Deficiency | Cognitive Development | Helminthic InfectionEthiopia
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Ondine Biomedical Inc.CompletedSurgical Site Infection | Nosocomial Infection | Healthcare Associated InfectionUnited States
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site InfectionUnited States
-
Croydon Health Services NHS TrustCompletedSurgical Site Infection | Wound Infection | Cesarean Section; Infection | Perineal InfectionUnited Kingdom
-
Cairo UniversityRecruitingPostoperative Infection | Cesarean Section Complications | Vaginal InfectionEgypt
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... and other collaboratorsRecruitingProsthetic-joint Infection | Infection Hip | Infection; Knee, JointNetherlands
-
Vastra Gotaland RegionGöteborg UniversityRecruitingProsthetic Joint Infection | Hip Prosthesis Infection | Prosthetic Infection | Knee Prosthesis InfectionSweden
-
University of ZurichCompletedProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical SiteSwitzerland
-
University of ZurichCompletedProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical SiteSwitzerland
Clinical Trials on Oxfendazole
-
Johns Hopkins Bloomberg School of Public HealthUniversidad Peruana Cayetano Heredia; School of Veterinary Medicine, Universidad...WithdrawnTenia Solium Infection
-
Johns Hopkins Bloomberg School of Public HealthUniversidad Peruana Cayetano HerediaWithdrawn
-
National Institute of Allergy and Infectious Diseases...CompletedNeurocysticercosisUnited States
-
Swiss Tropical & Public Health InstituteDrugs for Neglected Diseases; Ifakara Health InstituteCompleted
-
Universidad Peruana Cayetano HerediaNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting
-
Asociacion Benefica PrismaUniversity of Iowa; National Institutes of Health (NIH); University of Virginia; Policlinico Asociacion Benefica PRISMA-Laboratorio Satelite IQTLABNot yet recruiting
-
Oxfendazole Development GroupUniversidad Peruana Cayetano Heredia, Lima, PeruNot yet recruiting
-
University of ArkansasNational Institutes of Health (NIH); Ortho Biotech Clinical Affairs, L.L.C.Completed